Aethlon Medical, Inc.

And welcome to the Athlon Medical first quarter fiscal 2024 earnings and corporate update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Jim Frakes, Chief Financial Officer. Please go ahead.

Thank you, operator, and good afternoon, everyone. Welcome to Affon Medical's first quarter fiscal 2024 earnings conference call. My name is Jim Frakes, and I'm Affon's Chief Financial Officer. At 4.15 p.m. Eastern time today, Athlon Medical released financial results for its first fiscal quarter ended June 30, 2023. If you have not seen or received Athlon Medical's earnings release, please visit the investors page at www.athlonmedical.com. Following this introduction and the reading of our forward-looking statement, Athlon's Chief Executive Officer, Dr. Charles J. Fisher, Jr., and our Chief Medical Officer, Dr. Steven LaRosa, provide an overview of Athlon's strategy and recent developments. I will then make some brief remarks on Athlon's financials. We will then open up the call for the Q&A session. Before I hand the call over to Dr. LaRosa, please note that the news released today and this call contain forward-looking statements within the meaning of the Securities Act of 1933 as amended and the Securities Exchange Act of 1934 as amended. The company cautions you that any statement that is not a statement of historical fact is a forward-looking statement. These statements are based on expectations and assumptions as of the date of this conference call. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption risk factors in the company's annual report on Form 10-K for the fiscal year ended March 31, 2023, our most recent report on Form 10-Q, and in the company's other filings with the Securities and Exchange Commission. Except as may be required by law, the company does not intend nor does it undertake any duty to update this information in future circumstances. With that, I will now turn the call over to Dr. Steven LaRosa, Athlon's Chief Medical Officer.

Thank you, Jim, and thank all of you for dialing in. Hi, this is Steven LaRosa. Due to the timing of our March 31st fiscal year, this first quarter report falls only about five weeks after our recent call on June 28th. Athlon Medical is continuing the research and clinical development of its hemopurifier, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from the blood. These qualities of the hemopurifier have potential applications in oncology where cancer-associated may promote immune suppression and metastasis, as well as in life-threatening infectious diseases and the organ transplant field. Our ongoing COVID-19 trial in India for patients in the intensive care unit at Medanta Medicity Hospital remains open for enrollment. with one patient treated today. In May 2023, a second clinical site, Malana Azad Medical College, known as MAMC, received ethics board approval to participate in the trial, and site activation activities are currently underway. Patients with COVID-19 infections that require hospitalization continue to occur in India, and the addition of MAMC as a second high-quality clinical site may improve the enrollment of patients who go on to require ICU care for severe infection. In the oncology indication, Athlon Medical continues to work with its contract research organization, NAMSA LLC, to initiate a clinical study in Australia. Specifically, this is a safety, feasibility, and dose-finding trial in solid tumors failing treatment with anti-PD-1 antibodies. Athlon Medical believes that the data generated from this trial will help inform the design of future oncology efficacy trials of the company's hemopurifier. Ongoing activities include site identification and qualification, finalization of necessary documents for ethics board submission, the case report form development, and selection of a data safety monitoring board. With that, I will now turn the call over to Dr. Charles J. Fisher, Athlon's chief executive officer.